RZLT - Rezolute, Inc.

3.07
-0.240   -7.818%

Share volume: 1,297,060
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$3.31
-0.24
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
52%
Profitability 35%
Dept financing 27%
Liquidity 50%
Performance 75%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.97%
1 Month
7.72%
3 Months
-5.54%
6 Months
-67.79%
1 Year
-20.47%
2 Year
17.62%
Key data
Stock price
$3.07
P/E Ratio 
0.00
DAY RANGE
$3.05 - $3.36
EPS 
-$0.94
52 WEEK RANGE
$1.07 - $11.46
52 WEEK CHANGE
-$18.35
MARKET CAP 
218.837 M
YIELD 
N/A
SHARES OUTSTANDING 
95.698 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
-0.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,688,798
AVERAGE 30 VOLUME 
$1,541,081
Company detail
CEO: Nevan C. Elam
Region: US
Website: rezolutebio.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rezolute, Inc. develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

Recent news